Yanqiang Wang1, Sandya Liyanarachchi1, Katherine E Miller2, Taina T Nieminen1, Daniel F Comiskey1, Wei Li1, Pamela Brock3, David E Symer4, Keiko Akagi5, Katherine E DeLap3, Huiling He1, Daniel C Koboldt2, Albert de la Chapelle1. 1. 1Human Cancer Genetics Program and Department of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 2. 2Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio. 3. 3Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 4. 4Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas. 5. 5Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
Background: Familial non-medullary thyroid cancer (NMTC) accounts for a relatively small proportion of thyroid cancer cases, but it displays strong genetic predisposition. So far, only a few NMTC susceptible genes and low-penetrance variants contributing to NMTC have been described. This study aimed to identify rare germline variants that may predispose individuals to NMTC by sequencing a cohort of 17 NMTC families. Methods: Whole-genome sequencing and genome-wide linkage analysis were performed in 17 NMTC families. MendelScan and BasePlayer were applied to screen germline variants followed by customized filtering. The remaining candidate variants were subsequently validated by Sanger sequencing. A panel of 277 known cancer predisposition genes was also screened in these families. Results: A total of 41 rare coding candidate variants in 40 genes identified by whole-genome sequencing are reported, including 24 missense, five frameshift, five splice change, and seven nonsense variants. Sanger sequencing confirmed all 41 rare variants and proved their co-segregation with NMTC in the extended pedigrees. In silico functional analysis of the candidate genes using Ingenuity Pathway Analysis showed that cancer was the top category of "Diseases and Disorders." Additionally, a targeted search displayed six variants in known cancer predisposition genes, including one frameshift variant and five missense variants. Conclusions: The data identify rare germline variants that may play important roles in NMTC predisposition. It is proposed that in future research including functional characterization, these variants and genes be considered primary candidates for thyroid cancer predisposition.
Background: Familial non-medullary thyroid cancer (NMTC) accounts for a relatively small proportion of thyroid cancer cases, but it displays strong genetic predisposition. So far, only a few NMTC susceptible genes and low-penetrance variants contributing to NMTC have been described. This study aimed to identify rare germline variants that may predispose individuals to NMTC by sequencing a cohort of 17 NMTC families. Methods: Whole-genome sequencing and genome-wide linkage analysis were performed in 17 NMTC families. MendelScan and BasePlayer were applied to screen germline variants followed by customized filtering. The remaining candidate variants were subsequently validated by Sanger sequencing. A panel of 277 known cancer predisposition genes was also screened in these families. Results: A total of 41 rare coding candidate variants in 40 genes identified by whole-genome sequencing are reported, including 24 missense, five frameshift, five splice change, and seven nonsense variants. Sanger sequencing confirmed all 41 rare variants and proved their co-segregation with NMTC in the extended pedigrees. In silico functional analysis of the candidate genes using Ingenuity Pathway Analysis showed that cancer was the top category of "Diseases and Disorders." Additionally, a targeted search displayed six variants in known cancer predisposition genes, including one frameshift variant and five missense variants. Conclusions: The data identify rare germline variants that may play important roles in NMTC predisposition. It is proposed that in future research including functional characterization, these variants and genes be considered primary candidates for thyroid cancer predisposition.
Authors: Cezary Cybulski; Dominika Wokołorczyk; Józef Kładny; Grzegorz Kurzawski; Grzegorz Kurzwaski; Joanna Suchy; Ewa Grabowska; Jacek Gronwald; Tomasz Huzarski; Tomasz Byrski; Bohdan Górski; Tadeusz D Ecedil Bniak; Steven A Narod; Jan Lubiński Journal: Eur J Hum Genet Date: 2006-11-15 Impact factor: 4.246
Authors: O Alsanea; N Wada; K Ain; M Wong; K Taylor; P H Ituarte; P A Treseler; H U Weier; N Freimer; A E Siperstein; Q Y Duh; H Takami; O H Clark Journal: Surgery Date: 2000-12 Impact factor: 3.982
Authors: Elly S W Ngan; Brian H H Lang; Tingting Liu; Cathy K Y Shum; Man-Ting So; Danny K C Lau; Thomas Y Y Leon; Stacey S Cherny; Sophia Y Tsai; Chung-Yau Lo; Ui-Soon Khoo; Paul K H Tam; Maria-Mercè Garcia-Barceló Journal: J Natl Cancer Inst Date: 2009-01-27 Impact factor: 13.506
Authors: Julius Gudmundsson; Patrick Sulem; Daniel F Gudbjartsson; Jon G Jonasson; Asgeir Sigurdsson; Jon T Bergthorsson; Huiling He; Thorarinn Blondal; Frank Geller; Margret Jakobsdottir; Droplaug N Magnusdottir; Sigurborg Matthiasdottir; Simon N Stacey; Oskar B Skarphedinsson; Hafdis Helgadottir; Wei Li; Rebecca Nagy; Esperanza Aguillo; Eduardo Faure; Enrique Prats; Berta Saez; Mariano Martinez; Gudmundur I Eyjolfsson; Unnur S Bjornsdottir; Hilma Holm; Kristleifur Kristjansson; Michael L Frigge; Hoskuldur Kristvinsson; Jeffrey R Gulcher; Thorvaldur Jonsson; Thorunn Rafnar; Hannes Hjartarsson; Jose I Mayordomo; Albert de la Chapelle; Jon Hrafnkelsson; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson Journal: Nat Genet Date: 2009-02-06 Impact factor: 38.330
Authors: E H Seppälä; T Ikonen; N Mononen; V Autio; A Rökman; M P Matikainen; T L J Tammela; J Schleutker Journal: Br J Cancer Date: 2003-11-17 Impact factor: 7.640
Authors: Sandya Liyanarachchi; Julius Gudmundsson; Egil Ferkingstad; Huiling He; Jon G Jonasson; Vinicius Tragante; Folkert W Asselbergs; Li Xu; Lambertus A Kiemeney; Romana T Netea-Maier; Jose I Mayordomo; Theo S Plantinga; Hannes Hjartarson; Jon Hrafnkelsson; Erich M Sturgis; Pamela Brock; Fadi Nabhan; Gudmar Thorleifsson; Matthew D Ringel; Kari Stefansson; Albert de la Chapelle Journal: Proc Natl Acad Sci U S A Date: 2020-03-04 Impact factor: 11.205
Authors: Huiling He; Wei Li; Daniel F Comiskey; Sandya Liyanarachchi; Taina T Nieminen; Yanqiang Wang; Katherine E DeLap; Pamela Brock; Albert de la Chapelle Journal: Thyroid Date: 2020-02 Impact factor: 6.568
Authors: Taina T Nieminen; Christopher J Walker; Alisa Olkinuora; Luke K Genutis; Margaret O'Malley; Paul E Wakely; Lisa LaGuardia; Laura Koskenvuo; Johanna Arola; Anna H Lepistö; Pamela Brock; Ayse Selen Yilmaz; Ann-Kathrin Eisfeld; James M Church; Päivi Peltomäki; Albert de la Chapelle Journal: Thyroid Date: 2020-03 Impact factor: 6.568
Authors: Marta Sarquis; Debora C Moraes; Luciana Bastos-Rodrigues; Pedro G Azevedo; Adauto V Ramos; Fabiana Versiani Reis; Paula V Dande; Isabela Paim; Eitan Friedman; Luiz De Marco Journal: Endocr Pathol Date: 2020-03 Impact factor: 3.943
Authors: Taina T Nieminen; Sandya Liyanarachchi; Daniel F Comiskey; Yanqiang Wang; Wei Li; Isabella V Hendrickson; Pamela Brock; Albert de la Chapelle; Huiling He Journal: Mol Genet Genomic Med Date: 2021-05-04 Impact factor: 2.183
Authors: Daniel F Comiskey; Huiling He; Sandya Liyanarachchi; Mehek S Sheikh; Isabella V Hendrickson; Lianbo Yu; Pamela L Brock; Albert de la Chapelle Journal: Sci Rep Date: 2020-11-17 Impact factor: 4.379